Research Peptide

PT-141 For Sale (Research Use): The Melanocortin Peptide, Trials, and COA

Updated · 5 cited sources · ResearchChem Research Team

Short answer: ResearchChem supplies PT-141 (bremelanotide) as a research-use vial at 10 mg for $45, with every lot shipped with a lot number and a Certificate of Analysis sent on request. PT-141 is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH); it acts as an agonist at the central melanocortin-3 and melanocortin-4 receptors. The research literature studies it as a centrally-acting melanocortin agonist, separate from the FDA-approved product Vyleesi (also bremelanotide) that Palatin markets for one specific human indication. The research vial is supplied for in-vitro and animal research only.

The PT-141 research vial, exactly as shipped

  • SKU: PT141-10. Size: 10 mg lyophilized peptide in one vial.
  • Price: $45 (/shop/pt-141).
  • Shipping: US domestic, cold-chain insulated — no customs hold.
  • Compliance line on the 40×20 mm label: "RESEARCH USE ONLY · NOT FOR HUMAN USE".
  • COA: the lot-specific Certificate of Analysis is sent on request — email [email protected] with the lot number from the vial.
  • Storage: unopened at −20 °C; reconstitute with bacteriostatic water for in-vitro use.

Every order of $50 or more also receives one 100 mg GHK-Cu research vial free (SKU GHKCU-100); see free GHK-Cu with any $50 order for the exact offer terms.

What PT-141 is as a compound

PT-141 is bremelanotide, a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). The Molinoff 2003 characterization paper describes it as a synthetic alpha-MSH analog that acts as an agonist at the melanocortin-3 and melanocortin-4 receptors (MC3R / MC4R), which are expressed primarily in the central nervous system [1]. In that paper, systemic exposure in rats raised c-Fos signal in hypothalamic neurons, and a pseudorabies tracer placed into the rat corpus cavernosum later labelled the same hypothalamic region — evidence the authors cited for a central (not peripheral-vascular) site of action.

The structural ancestor of PT-141 is the melanotan-II scaffold; bremelanotide is the carboxylic-acid metabolite of melanotan-II without the C-terminal amide. That structural change is why bremelanotide is studied specifically for melanocortin-receptor pharmacology rather than for pigmentation.

What peer-reviewed trials have reported

The preclinical female-rat work by Pfaus and colleagues (PNAS 2004) reported that PT-141 selectively increased sexual-solicitation behaviors in female rats after peripheral (subcutaneous) delivery and after direct infusion into the lateral ventricles or medial preoptic area, without altering pacing, lordosis, or general locomotor activity [2]. The authors interpreted the effect as mediated by central melanocortin receptors in sexually-dimorphic hypothalamic circuits.

The first human proof-of-concept study in premenopausal women was Diamond and colleagues, J Sex Med 2006 — a double-blind single-session evaluation of an intranasal 20 mg dose of bremelanotide vs placebo in 18 premenopausal women with sexual arousal disorder [3]. More women reported moderate or high sexual desire after bremelanotide than after placebo (P = 0.0114). Vaginal vasocongestion during erotic videos did not differ significantly between arms; the authors called the trial a preliminary evaluation supporting further study.

The Phase 3 trials (RECONNECT-1 and RECONNECT-2, pooled in Kingsberg and colleagues, Obstet Gynecol 2019) randomized 1,247 premenopausal women with hypoactive sexual desire disorder to 24 weeks of subcutaneous bremelanotide or placebo. Both co-primary endpoints — change in desire score and change in distress score — favored bremelanotide at P < 0.001 [4]. Nausea, flushing, and headache were each reported by at least 10% of participants in both studies. An open-label extension in the same journal volume (Simon and colleagues, Obstet Gynecol 2019) reported sustained effect and no new safety signals across an additional 52 weeks [5]. On the strength of these data, the FDA approved subcutaneous bremelanotide as Vyleesi for premenopausal HSDD in June 2019.

The numbers above are measurements from the cited peer-reviewed trials. The ResearchChem vial is supplied for in-vitro and animal research only; the paragraphs are not instructions for use.

What the COA on a PT-141 lot shows

Fields a PT-141 (bremelanotide) lot COA should carry
FieldWhat it tells youWhat to check
Lot numberWhich production run the results belong toMatches the lot printed on the vial
Sequence or formulaWhich molecule was testedAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH reported, or the standard bremelanotide empirical formula C50H68N14O10
Identity (MS)Measured molecular mass vs theoretical massObserved monoisotopic mass matches the 1025.17 Da theoretical value
Purity (HPLC)Share of UV-absorbing material that is the main peakA percentage value plus the chromatogram
Methods and limitsHow each result was produced and what counts as a passAcceptance criteria next to every result
Lab, date, sign-offWho tested it and whenLab name, analysis date, analyst or QA signature

See how to read a peptide COA for a field-by-field walkthrough. The purity figure is covered in more detail in HPLC peptide purity explained.

US-domestic sourcing

For US-based research use, a supplier should ship from within the US, supply a lot-specific COA on request, and label every vial with the standard RUO compliance line. ResearchChem carries the research vial at /shop/pt-141 for $45, shipped cold-chain. The FDA-approved bremelanotide product (Vyleesi) is a prescription drug sold through pharmacies on the authority of a prescribing clinician; it is not the same supply as the research vial and the two are not interchangeable.

Frequently asked questions

Can I buy PT-141 for research use in the US?

Yes. ResearchChem supplies the research vial at /shop/pt-141 (10 mg, $45), shipped from within the US. Every vial carries the RUO compliance line and the lot-specific COA is sent on request.

What is PT-141 as a compound?

A cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It acts as an agonist at the central melanocortin-3 and melanocortin-4 receptors.

Is PT-141 an approved drug?

Subcutaneous bremelanotide is approved by the FDA as Vyleesi, for one specific premenopausal human indication, on the authority of a prescribing clinician. The ResearchChem research vial is a separate supply, labelled research use only and shipped without a prescription for in-vitro and animal research.

What papers document PT-141?

Molinoff 2003 (Ann N Y Acad Sci) characterized the melanocortin-receptor mechanism. Pfaus 2004 (PNAS) reported the selective-solicitation effect in female rats. Diamond 2006 (J Sex Med) was the first human proof-of-concept. Kingsberg 2019 and Simon 2019 (Obstet Gynecol) reported the Phase 3 and open-label extension data behind the Vyleesi approval.

Does the COA cover the whole lot?

Yes. The lot-specific COA is generated once per production run and applies to every vial that carries that lot number.

Cited studies

  1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction.. Ann N Y Acad Sci. 994:96-102 (2003). PubMed 12851303 DOI
  2. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.. Proc Natl Acad Sci U S A. 101(27):10201-10204 (2004). PubMed 15226502 DOI
  3. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.. J Sex Med. 3(4):628-638 (2006). PubMed 16839319 DOI
  4. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.. Obstet Gynecol. 134(5):899-908 (2019). PubMed 31599840 DOI
  5. Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.. Obstet Gynecol. 134(5):909-917 (2019). PubMed 31599847 DOI

Related compounds

  • PT-141 — Melanocortin Peptide

Keep reading

Research use only. ResearchChem products are laboratory reagents for in-vitro research. They are not for human or veterinary consumption and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published research for educational purposes and is not medical advice.